Abstract
Objective: Compare time to pain relief (minimum of a 13 mm and 30% reduction) during an Emergency Department (ED) visit among patients with sickle cell disease (SCD) experiencing severe pain associated with a vaso-occlusive episode who were randomized to receive either an individualized or weight-based pain protocol. Methods: A randomized controlled trial in two EDs. Adults with sickle cell disease. Research staff recorded pain scores every 30 min during an ED visit (up to 6 h in the ED) using a 0–100 mm visual analogue scale. Analysis included 122 visits, representing 49 patients (individualized: 61 visits, 25 patients; standard: 61 visits, 24 patients). Results: Pain reduction across 6-h was greater for the individualized compared to the standard protocol (protocol-by-time: p =.02; 6-h adjusted pain score comparison: Individualized: M = 29.2, SD = 38.8, standard: M = 45.3, SD = 35.6; p =.03, Cohen d = 0.43). Hazards models indicated a greater probability of 13 mm (HR = 1.54, 95% CI = 1.05, 2.27, p =.03) and 30% (HR = 1.71, 95% CI = 1.11, 2.63, p =.01) reduction in the individualized relative to the standard protocol. Conclusions: Patients who received treatment with an individualized protocol experienced a more rapid reduction in pain, including a 13 mm and 30% reduction in pain scores when compared to those that received weight-based dosing.
Original language | English (US) |
---|---|
Pages (from-to) | 518-526 |
Number of pages | 9 |
Journal | European Journal of Haematology |
Volume | 110 |
Issue number | 5 |
DOIs | |
State | Published - May 2023 |
Funding
Dr's. Crawford, Miller, Paice and Silva have not conflicts of interest. Dr. Tanabe is a consultant for CSL Behring and received NIH funding. Dr. Bosworth reports research funding from: BeBetter Thereaputics, Boehringer Ingelheim, Esperion, Improved Patient Outcomes, Merck, NHLBI, Novo NOrdisk, Otsuka, Sanofi, VA, Elton John Foundation, Hilton Foundation, and Pfizer. Dr. Bosworth is a consultant for Abbott, Imatar, Novartis, Sanofi, Vidya, Walmart, Webmed, and is on the Board of Directors for Preventric Diagnostics. Dr. Glassberg has funding from the NIH and the Doris Duke Charitable Foundation is a consultant for CSLF Behring, Novartis, and on the DSMB for Synforma Syynteract. This project was funded by NHLBI, R34 RHL121224A.
Keywords
- emergency
- pain
- sickle cell
- vaso-occlusive episodes
ASJC Scopus subject areas
- Hematology